2.Other agents within the class of GLP-1 RA or GLP-1 RA /GIP RA dual agonists can be used for the improvement of glycemic control with a low risk of both hypoglycemia and beneficial effects of weight loss in obese people with T2DM and CKD (Grade 1A). The gene discussed is GCG; the disease is chronic kidney disease.